Gail Connor Roche

Nucleic acid testing indicates whether a virus is present by detecting and amplifying its RNA or DNA.

These guidelines are safe and effective primary prevention tools to potentially reduce new HIV infections in Canada.

The natural flavonoid isolates from Brazilian plants could serve as a hepatitis C treatment template.

The studied patients 1 of 2 different HCV genotypes had prior failures when treated with DAA therapies that consisted of at least 1 NS3/4A protease and/or NS5A inhibitor-containing medication.

Researchers reevaluated clinical guidelines from clinical developments in the past 12 years.

While the world is reducing new HIV infections and AIDS-related deaths, substantial challenges remain.

Researchers found that viral load can predict SVR rates nearly 1 month into DAA therapy.

Patients with HIV are at risk of CVD and CKD, and the likelihood increases significantly as risk levels rise.

Patients co-infected with Hepatitis C and HIV reported similar sustained virologic responses to those of solely HCV-infected patients.

The international humanitarian aid group will get the generics from companies in Egypt and India.

“There is overwhelming evidence that early ART is beneficial for HIV-positive children," Marcin Jankiewicz, PhD, MSci, said.

Based on current policies, the US is 1 of 22 nations "working towards" HCV elimination.

The research team gauged nearly 3,500 HCV patients who had attained SVR on sofosbuvir.

Aspirin is known for its strong anti-inflammatory properties, and has been explored for its chemopreventive effects in cancers related to chronic inflammation.

As many as 8% of pregnant women worldwide are infected with HCV.

While about 5% of HIV is genetically intact, the small percentage prevents the immune system from fully destroying HIV.

“Developing novel ideas to further improve HCV screening and linkage to care are needed."

Young injection drug users with HCV benefit from a cost-effective method of viral testing.

Those taking ART and achieve an undetectable viral load have effectively no risk of transmitting it to non-infected partners.

The effectiveness of these DAAs on such patients has not been evaluated, even though the prevalence of the liver-attacking virus among heart recipients ranges from 7% to 18%.

Co-receptor agonists and fusion inhibitors are designed to have a synergized function. Why doesn't it always happen?

HCV-positive women of childbearing age undergo premature ovarian deterioration, researchers wrote.

All of the 13 patients with genotype 2 achieved SVR after 12 weeks of treatment, and in those with genotype 3, the SVR rate was 97%.

While 52% of patients were eligible for treatment, only 60% of them received it. For the 47% of individuals who weren’t eligible, the most common reason was their inability to provide pre-treatment workups including serologic testing and assessment for liver fibrosis and inflammation.

Worldwide HCV prevalence in 2017 dropped 2% from 2015 levels to 69.6 million viremic infections, thanks to increased treatment and prevention.

The genomes associated with a higher risk of CHD are also associated with higher T2D risk, revealing the possibility of a treatment for both.

Direct-acting antiviral sofosbuvir has had a high success rate in treating chronic HCV. But the potential for toxicity to the kidneys has raised some concern, especially in patients with CKD.

A substance known as epicatechin monomers helps the body release more insulin and respond more efficiently to increased blood glucose, which could in turn benefit type 2 diabetics.

Women with type 1 diabetes carry a higher risk of AFib than both men and the general public as a whole.

Researchers noted that some previous studies have found that sex hormones play a role in faster progression.